Furthermore, for [18F]PSMA-1007 median SUVmax of primary tumour was, compared to [18F]DCFPyL and [68Ga]Ga-PSMA-11, relatively close to median SUVmax liver and spleen (Table 3), which may have posed an additional challenge to consistently assess the PSMA expression score of the primary tumour related to these reference organs. Therefore, it is important to acknowledge the applied PROMISE criteria (V1 or V2) and the presence of differences in interobserver agreement of PSMA-expression scores when using different PSMA PET tracers [5, 6]. This evidence concerns the gene FOLH1 and neoplasm.